

# Noninvasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography

Liver International

32, 911-918

DOI: [10.1111/j.1478-3231.2012.02820.x](https://doi.org/10.1111/j.1478-3231.2012.02820.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Management of Nonalcoholic Fatty Liver Disease. JAMA - Journal of the American Medical Association, 2012, 308, 608-16.	3.8	18
2	Controlled attenuation parameter (<scp>CAP</scp>): a new device for fast evaluation of liver fat?. Liver International, 2012, 32, 875-877.	1.9	24
3	Non-Invasive Evaluation of Liver Steatosis, Fibrosis and Cirrhosis in Hepatitis C Virus Infected Patients Using Unidimensional Transient Elastography (Fibroscan®). , 0, , .		3
4	Noninvasive evaluation of NAFLD. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 666-675.	8.2	238
5	Utility of controlled attenuation parameter measurement for assessing liver steatosis in <scp>apanese patients with chronic liver diseases. Hepatology Research, 2013, 43, 1182-1189.	1.8	55
6	Diagnostic imaging in obesity. Best Practice and Research in Clinical Endocrinology and Metabolism, 2013, 27, 261-277.	2.2	35
7	Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. Journal of Hepatology, 2013, 58, 1007-1019.	1.8	332
8	Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography. European Journal of Gastroenterology and Hepatology, 2013, 25, 1330-1334.	0.8	32
9	Serum carcinoembryonic antigen is associated with non-alcoholic fatty liver disease in healthy Korean non-smokers. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1499-504.	1.4	15
10	Influence of heterogeneities on ultrasound attenuation for liver steatosis evaluation (CAP&#x2122;): Relevance of a liver guidance tool. , 2013, , .		2
11	Interobserver concordance in controlled attenuation parameter measurement, a novel tool for the assessment of hepatic steatosis on the basis of transient elastography. European Journal of Gastroenterology and Hepatology, 2013, 25, 905-911.	0.8	32
12	Pathogenesis, diagnosis and treatment of non-alcoholic fatty liver disease. Revista Espanola De Enfermedades Digestivas, 2013, 105, 409-420.	0.1	36
13	Liver elastography, comments on EFSUMB elastography guidelines 2013. World Journal of Gastroenterology, 2013, 19, 6329.	1.4	51
14	Non-alcoholic fatty liver disease and diabetes: From physiopathological interplay to diagnosis and treatment. World Journal of Gastroenterology, 2014, 20, 8377.	1.4	76
15	Non-Invasive Assessment of Hepatic Steatosis in Patients with NAFLD Using Controlled Attenuation Parameter and 1H-MR Spectroscopy. PLoS ONE, 2014, 9, e91987.	1.1	130
16	Biomarkers in Nonalcoholic Fatty Liver Disease. Canadian Journal of Gastroenterology and Hepatology, 2014, 28, 607-618.	0.8	122
17	Diagnosis of alcoholic liver disease. World Journal of Gastroenterology, 2014, 20, 11684.	1.4	115
18	Invasive and non-invasive diagnosis of cirrhosis and portal hypertension. World Journal of Gastroenterology, 2014, 20, 4300.	1.4	98

#	ARTICLE	IF	CITATIONS
19	Non invasive tools for the diagnosis of liver cirrhosis. World Journal of Gastroenterology, 2014, 20, 18131.	1.4	76
20	Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. World Journal of Gastroenterology, 2014, 20, 4702.	1.4	92
21	Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2014, 20, 8393.	1.4	118
22	Non-Alcoholic Fatty Liver Disease: Diagnosis and Investigation. Digestive Diseases, 2014, 32, 586-596.	0.8	10
23	Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1470-1476.	1.4	148
24	Effects of air embolism size and location on porcine hepatic microcirculation in machine perfusion. Liver Transplantation, 2014, 20, 601-611.	1.3	5
25	Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV-infected patients. Aids, 2014, 28, 1279-1287.	1.0	59
26	Interobserver reproducibility of the controlled attenuation parameter (CAP) for quantifying liver steatosis. Hepatology International, 2014, 8, 576-581.	1.9	32
27	Noninvasive assessment of liver steatosis using ultrasound methods. Medical Ultrasonography, 2014, 16, 236-45.	0.4	43
28	4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine—recommendations for facing obesity, fatty liver and fibrosis epidemics. EPMA Journal, 2014, 5, 21.	3.3	29
29	Current status of fibrosis markers. Current Opinion in Gastroenterology, 2014, 30, 253-259.	1.0	38
30	Controlled attenuation parameter (<math>CAP</math>) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. Liver International, 2014, 34, 102-109.	1.9	143
31	Getting closer to a point-of-care diagnostic assessment in patients with chronic liver disease: Controlled attenuation parameter for steatosis. Journal of Hepatology, 2014, 60, 910-912.	1.8	35
32	Utilization of FibroScan in Clinical Practice. Current Gastroenterology Reports, 2014, 16, 372.	1.1	101
33	How good is controlled attenuation parameter and fatty liver index for assessing liver steatosis in general population: correlation with ultrasound. Liver International, 2014, 34, e111-7.	1.9	70
34	Assessment of liver volume with computed tomography and comparison of findings with ultrasonography. Abdominal Imaging, 2014, 39, 1153-1161.	2.0	10
36	Controlled attenuation parameter (CAP) for the diagnosis of steatosis: A prospective study of 5323 examinations. Journal of Hepatology, 2014, 60, 1026-1031.	1.8	318
37	Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: A meta-analysis of diagnostic accuracy. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1149-1158.	1.4	132

#	ARTICLE	IF	CITATIONS
39	Mouse Liver Dispersion for the Diagnosis of Early-Stage Fatty Liver Disease: A 70-Sample Study. <i>Ultrasound in Medicine and Biology</i> , 2014, 40, 704-713.	0.7	65
40	Detection of hepatic steatosis using the controlled attenuation parameter: a comparative study with liver biopsy. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 611-616.	0.6	31
41	Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C. <i>Hepatology</i> , 2014, 60, 65-76.	3.6	118
42	Ultrasound in chronic liver disease. <i>Insights Into Imaging</i> , 2014, 5, 441-455.	1.6	88
43	The Diagnostic Accuracy of Transient Elastography for the Diagnosis of Liver Fibrosis in Bariatric Surgery Candidates with Suspected NAFLD. <i>Obesity Surgery</i> , 2014, 24, 1693-1701.	1.1	75
44	Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. <i>World Journal of Gastroenterology</i> , 2014, 20, 475.	1.4	453
45	Controlled Attenuation Parameter and Liver Stiffness Measurements for Steatosis Assessment in the Liver Transplant of Brain Dead Donors. <i>Transplantation</i> , 2015, 99, 1619-1624.	0.5	24
46	Estimating steatosis and fibrosis: Comparison of acoustic structure quantification with established techniques. <i>World Journal of Gastroenterology</i> , 2015, 21, 4894.	1.4	37
47	Associations of Erythrocyte Fatty Acids in the De Novo Lipogenesis Pathway with Proxies of Liver Fat Accumulation in the EPIC-Potsdam Study. <i>PLoS ONE</i> , 2015, 10, e0127368.	1.1	25
48	Transient Elastography-Based Liver Profiles in a Hospital-Based Pediatric Population in Japan. <i>PLoS ONE</i> , 2015, 10, e0137239.	1.1	54
49	Diagnostic performance of controlled attenuation parameter for predicting steatosis grade in chronic hepatitis B. <i>Annals of Hepatology</i> , 2015, 14, 826-836.	0.6	18
50	Noninvasive assessment of alcoholic liver disease using unidimensional transient elastography (Fibroscan®). <i>World Journal of Gastroenterology</i> , 2015, 21, 11914.	1.4	18
51	Non-invasive diagnostic approach to non-alcoholic fatty liver disease: current evidence and future perspectives. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1039-1053.	1.4	13
52	Non-alcoholic Fatty Liver Disease and Metabolic Syndrome—Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. <i>Journal of Clinical and Experimental Hepatology</i> , 2015, 5, 51-68.	0.4	122
53	Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 603-627.	1.4	102
54	Nonalcoholic fatty liver disease: Noninvasive methods of diagnosing hepatic steatosis. <i>Saudi Journal of Gastroenterology</i> , 2015, 21, 64.	0.5	26
55	New inverse problem for viscoelastic characterization of fatty liver using vibration controlled transient elastography. , 2015, , .		0
56	Liver stiffness and aspartate aminotransferase levels predict the risk for liver fibrosis progression in hepatitis C virus/HIV coinfected patients. <i>HIV Medicine</i> , 2015, 16, 211-218.	1.0	18

#	ARTICLE	IF	CITATIONS
57	Usefulness of liver test and controlled attenuation parameter in detection of nonalcoholic fatty liver disease in patients with chronic renal failure and coronary heart disease. <i>Wiener Klinische Wochenschrift</i> , 2015, 127, 451-458.	1.0	14
58	Fat and Fiber: How the Controlled Attenuation Parameter Complements Noninvasive Assessment of Liver Fibrosis. <i>Digestive Diseases and Sciences</i> , 2015, 60, 9-12.	1.1	12
59	Correlation of the controlled attenuation parameter with indices of liver steatosis in overweight or obese individuals. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 305-312.	0.8	10
60	Noninvasive characterization of graft steatosis after liver transplantation. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 224-232.	0.6	28
61	Controlled Attenuation Parameter for Noninvasive Assessment of Hepatic Steatosis Using Fibroscan <sup>®</sup> : Validation in Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2015, 60, 243-251.	1.1	35
62	Diagnostic value of alcoholic liver disease (ALD)/nonalcoholic fatty liver disease (NAFLD) index combined with <sup>13</sup> C-glutamyl transferase in differentiating ALD and NAFLD. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 479-487.	0.7	18
63	Transient elastography (FibroScan <sup>®</sup> ) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?. <i>World Journal of Gastroenterology</i> , 2016, 22, 7236.	1.4	193
64	Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2016, 11, e0157358.	1.1	62
65	Transient Elastography-Based Liver Stiffness Age-Dependently Increases in Children. <i>PLoS ONE</i> , 2016, 11, e0166683.	1.1	57
66	Evaluation of hepatic fibrosis " access to non-invasive methods, national practice/guidelines in Central Europe. <i>Clinical and Experimental Hepatology</i> , 2016, 1, 12-15.	0.6	7
67	Controlled attenuation parameter for the diagnosis of steatosis in nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 848-855.	1.4	151
68	PNPLA3 148M Carriers with Inflammatory Bowel Diseases Have Higher Susceptibility to Hepatic Steatosis and Higher Liver Enzymes. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 134-140.	0.9	27
69	Controlled attenuation parameter is correlated with actual hepatic fat content in patients with nonalcoholic fatty liver disease with none-to-mild obesity and liver fibrosis. <i>Hepatology Research</i> , 2016, 46, 1019-1027.	1.8	35
70	Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients. <i>HIV Medicine</i> , 2016, 17, 766-773.	1.0	23
71	Short-Term Hypocaloric High-Fiber and High-Protein Diet Improves Hepatic Steatosis Assessed by Controlled Attenuation Parameter. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e176.	1.3	29
72	Body mass index is associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 1071-1079.	1.9	33
73	The relationship between hepatic steatosis and skeletal muscle mass index in men with type 2 diabetes. <i>Endocrine Journal</i> , 2016, 63, 877-884.	0.7	57
74	The clinical value of controlled attenuation parameter for the noninvasive assessment of liver steatosis. <i>Liver International</i> , 2016, 36, 1860-1866.	1.9	19

#	ARTICLE	IF	CITATIONS
75	Randomized clinical trial: benefits of aerobic physical activity for 24 weeks in postmenopausal women with nonalcoholic fatty liver disease. <i>Menopause</i> , 2016, 23, 876-883.	0.8	44
76	Prevalence of hepatic steatosis in apparently healthy medical students: a transient elastography study on the basis of a controlled attenuation parameter. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 1264-1267.	0.8	18
77	MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice. <i>Journal of Hepatology</i> , 2016, 65, 1006-1016.	1.8	275
78	Controlled attenuation parameter for the detection of hepatic steatosis in patients with chronic hepatitis B. <i>Infectious Diseases</i> , 2016, 48, 670-675.	1.4	7
79	Letter: can persisting liver stiffness indicate increased risk of HCC, after successful anti-HCV therapy?. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 543-544.	1.9	9
80	Diagnostic Considerations and Clinical End Points for Nonalcoholic Steatohepatitis. , 2016, , 211-221.		0
81	The Correlation Between Obesity-Related Diseases and Non-alcoholic Fatty Liver Disease in Women in the Pre-operative Evaluation for Bariatric Surgery Assessed by Transient Hepatic Elastography. <i>Obesity Surgery</i> , 2016, 26, 2089-2097.	1.1	10
82	Non-alcoholic fatty liver disease and liver transplantation. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1208-1223.	1.5	40
83	Liver Steatosis Assessed by Controlled Attenuation Parameter (CAP) Measured with the XL Probe of the FibroScan: A Pilot Study Assessing Diagnostic Accuracy. <i>Ultrasound in Medicine and Biology</i> , 2016, 42, 92-103.	0.7	115
84	The common <i>PNPLA3</i> variant p.I148M is associated with liver fat contents as quantified by controlled attenuation parameter (CAP). <i>Liver International</i> , 2016, 36, 418-426.	1.9	24
85	Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population. <i>United European Gastroenterology Journal</i> , 2017, 5, 76-85.	1.6	67
86	Fat mass and obesity-associated gene variations are related to fatty liver disease in HIV-infected patients. <i>HIV Medicine</i> , 2017, 18, 546-554.	1.0	6
87	Liver fibrogenesis. , 2017, , 110-122.e5.		0
88	Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. <i>Journal of Hepatology</i> , 2017, 67, 577-584.	1.8	110
89	Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2150-2158.	1.1	18
90	Controlled attenuation parameter for diagnosing steatosis in bariatric surgery candidates with suspected nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 1022-1030.	0.8	28
91	A comparison of hepatic steatosis index, controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B. <i>Digestive and Liver Disease</i> , 2017, 49, 910-917.	0.4	45
92	Clinical usefulness of controlled attenuation parameter to screen hepatic steatosis for potential donor of living donor liver transplant. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 805-810.	0.8	26

#	ARTICLE	IF	CITATIONS
93	Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. <i>Journal of Hepatology</i> , 2017, 66, 1022-1030.	1.8	734
94	Diagnosing liver fibrosis: a narrative review of current literature for dermatologists. <i>British Journal of Dermatology</i> , 2017, 177, 637-644.	1.4	8
95	High value of controlled attenuation parameter predicts a poor antiviral response in patients with chronic hepatitis B. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2017, 16, 370-374.	0.6	12
96	The role of bariatric surgery in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 797-811.	1.4	24
97	Controlled attenuation parameter and magnetic resonance spectroscopy-measured liver steatosis are discordant in obese HIV-infected adults. <i>Aids</i> , 2017, 31, 2119-2125.	1.0	18
98	Fat Quantification in the Abdomen. <i>Topics in Magnetic Resonance Imaging</i> , 2017, 26, 221-227.	0.7	22
99	Potential impact of screening for fatty liver disease by transient elastography with liver stiffness and controlled attenuation parameter measurements: a pilot study. <i>Zeitschrift Fur Gastroenterologie</i> , 2017, 55, 754-760.	0.2	0
100	The inverse effect of meal intake on controlled attenuation parameter and liver stiffness as assessed by transient elastography. <i>BMC Gastroenterology</i> , 2017, 17, 50.	0.8	24
101	The clinical value of the controlled attenuation parameter in the follow-up of HIV-infected patients. <i>HIV Medicine</i> , 2017, 18, 444-444.	1.0	4
102	Assessment of transient elastography in Japanese patients with non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2017, 47, 882-889.	1.8	16
103	Non-invasive diagnosis of hepatic steatosis. <i>Hepatology International</i> , 2017, 11, 70-78.	1.9	101
104	Diagnostic Accuracy of Controlled Attenuation Parameter for Detecting Hepatic Steatosis in Patients with Chronic Liver Disease. <i>GE Portuguese Journal of Gastroenterology</i> , 2017, 24, 161-168.	0.3	15
105	Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Infectious Diseases</i> , 2017, 65, 1012-1019.	2.9	42
106	A Noninvasive Score Model for Prediction of NASH in Patients with Chronic Hepatitis B and Nonalcoholic Fatty Liver Disease. <i>BioMed Research International</i> , 2017, 2017, 1-7.	0.9	11
107	Imaging evaluation of non-alcoholic fatty liver disease: focused on quantification. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 290-301.	4.5	105
108	Protein and vitamin B6 intake are associated with liver steatosis assessed by transient elastography, especially in obese individuals. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 249-259.	4.5	20
109	Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 546-551.	0.8	43
110	Chronic liver diseases and the potential use of S-adenosyl-L-methionine as a hepatoprotector. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 893-900.	0.8	21

#	ARTICLE	IF	CITATIONS
111	Discordance in steatosis classification between liver biopsy and transient elastography for high controlled attenuation parameter (CAP) values. <i>Zeitschrift Fur Gastroenterologie</i> , 2018, 56, 36-42.	0.2	2
112	Clinical implications of controlled attenuation parameter in a health checkâ€p cohort. <i>Liver International</i> , 2018, 38, 915-923.	1.9	15
113	MR Spectroscopyâ€derived Proton Density Fat Fraction Is Superior to Controlled Attenuation Parameter for Detecting and Grading Hepatic Steatosis. <i>Radiology</i> , 2018, 286, 547-556.	3.6	79
114	Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography. <i>Clinics in Liver Disease</i> , 2018, 22, 73-92.	1.0	73
115	Ultrasound Entropy Imaging of Nonalcoholic Fatty Liver Disease: Association with Metabolic Syndrome. <i>Entropy</i> , 2018, 20, 893.	1.1	23
116	Predicting Hepatic Steatosis in Living Liver Donors Via Controlled Attenuation Parameter. <i>Transplantation Proceedings</i> , 2018, 50, 3533-3538.	0.3	18
117	Liver Fat Content and Body Fat Distribution in Youths with Excess Adiposity. <i>Journal of Clinical Medicine</i> , 2018, 7, 528.	1.0	18
118	Validity of ultrasonography to assess hepatic steatosis compared to magnetic resonance spectroscopy as a criterion method in older adults. <i>PLoS ONE</i> , 2018, 13, e0207923.	1.1	17
119	Relationship between Serum Cytokeratin-18, Control Attenuation Parameter, NAFLD Fibrosis Score, and Liver Steatosis in Nonalcoholic Fatty Liver Disease. <i>International Journal of Hepatology</i> , 2018, 2018, 1-9.	0.4	12
120	Quantitative Hepatic Fat Quantification in Non-alcoholic Fatty Liver Disease Using Ultrasound-Based Techniques: A Review of Literature and Their Diagnostic Performance. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 2461-2475.	0.7	80
121	Liver Ultrasound Elastography: An Update to the World Federation for Ultrasound in Medicine and Biology Guidelines and Recommendations. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 2419-2440.	0.7	357
122	Diagnosis and Characterization of Non-Alcoholic Fatty Liver Disease. , 0, , .		4
123	Usefulness of controlled attenuation parameter for detecting increased arterial stiffness in general population. <i>Digestive and Liver Disease</i> , 2018, 50, 1062-1067.	0.4	9
124	Controlled attenuation parameter in NAFLD identifies risk of suboptimal glycaemic and metabolic control. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 799-804.	1.2	10
125	Noninvasive Evaluation of Fibrosis and Steatosis in Nonalcoholic Fatty Liver Disease by Elastographic Methods. , 0, , .		2
126	The B-Mode Image-Guided Ultrasound Attenuation Parameter Accurately Detects Hepatic Steatosis in Chronic Liver Disease. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 2223-2232.	0.7	103
127	MEASUREMENT OF CONTROLLED ATTENUATION PARAMETER: A SURROGATE MARKER OF HEPATIC STEATOSIS IN PATIENTS OF NONALCOHOLIC FATTY LIVER DISEASE ON LIFESTYLE MODIFICATION - A PROSPECTIVE FOLLOW-UP STUDY. <i>Arquivos De Gastroenterologia</i> , 2018, 55, 7-13.	0.3	10
128	Return-to-health effect of modern combined antiretroviral therapy potentially predisposes HIV patients to hepatic steatosis. <i>Medicine (United States)</i> , 2018, 97, e0462.	0.4	29



#	ARTICLE	IF	CITATIONS
129	Prognostic Significance of Controlled Attenuation Parameter in Patients With Compensated Advanced Chronic Liver Disease. <i>Hepatology Communications</i> , 2018, 2, 933-944.	2.0	21
130	Reader agreement and accuracy of ultrasound features for hepatic steatosis. <i>Abdominal Radiology</i> , 2019, 44, 54-64.	1.0	16
131	PNPLA3 gene polymorphism in Brazilian patients with type 2 diabetes: A prognostic marker beyond liver disease?. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2019, 29, 965-971.	1.1	15
132	Transient liver elastography in normal pregnancy – a longitudinal cohort study. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 761-765.	0.6	26
133	Quantification of Liver Fat in NAFLD: Available Modalities and Clinical Significance. <i>Current Hepatology Reports</i> , 2019, 18, 492-502.	0.4	6
134	Open-label Study with Nalmefene as Needed Use in Alcohol-Dependent Patients with Evidence of Elevated Liver Stiffness and/or Hepatic Steatosis. <i>Alcohol and Alcoholism</i> , 2019, 55, 63-70.	0.9	11
135	Noninvasive and Convenient Screening of Metabolic Syndrome Using the Controlled Attenuation Parameter Technology: An Evaluation Based on Self-Paid Health Examination Participants. <i>Journal of Clinical Medicine</i> , 2019, 8, 1775.	1.0	14
136	A review of the use of transient elastography in the assessment of fibrosis and steatosis in the post-liver transplant patient. <i>Clinical Transplantation</i> , 2019, 33, e13700.	0.8	22
137	Long-Term Changes in Hepatic Fibrosis following Hepatitis C Viral Clearance in Patients with and without HIV. <i>Antiviral Therapy</i> , 2019, 24, 451-457.	0.6	9
138	Elastodiagnosis of diseases: A review. <i>Extreme Mechanics Letters</i> , 2019, 27, 102-123.	2.0	19
139	Transient Elastography and Controlled Attenuation Parameter (CAP) in the Assessment of Liver Steatosis in Severe Adult Growth Hormone Deficiency. <i>Frontiers in Endocrinology</i> , 2019, 10, 364.	1.5	7
140	Considerations of Ultrasound Scanning Approaches in Non-alcoholic Fatty Liver Disease Assessment through Acoustic Structure Quantification. <i>Ultrasound in Medicine and Biology</i> , 2019, 45, 1955-1969.	0.7	17
141	Diagnosis and management of non-alcoholic fatty liver disease. <i>Postgraduate Medical Journal</i> , 2019, 95, 314-322.	0.9	70
142	Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2019, 156, 1264-1281.e4.	0.6	882
143	Fibroblast growth factor 21 is independently associated with severe hepatic steatosis in non-obese HIV-infected patients. <i>Liver International</i> , 2019, 39, 1514-1520.	1.9	16
144	Branched chain amino acids are associated with the heterogeneity of the area of lipid droplets in hepatocytes of patients with non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2019, 49, 860-871.	1.8	15
145	Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2019, 156, 1717-1730.	0.6	777
146	Weight Gain and Liver Steatosis in Patients with Inflammatory Bowel Diseases. <i>Nutrients</i> , 2019, 11, 303.	1.7	10

#	ARTICLE	IF	CITATIONS
147	Liver Stiffness, Not Fat Liver Content, Predicts the Length of QTc Interval in Patients with Chronic Liver Disease. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-7.	0.7	2
148	HIV-Associated NAFLD: Disease Burden and Management. <i>Current Hepatology Reports</i> , 2019, 18, 482-491.	0.4	2
149	Fibroscan and low-density lipoprotein as determinants of severe liver fibrosis in diabetic patients with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1540-1544.	0.8	14
150	The clinical usefulness of elastography in the evaluation of nonalcoholic fatty liver disease patients: A biopsy-controlled study. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1010-1016.	0.8	9
151	Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. <i>American Journal of Gastroenterology</i> , 2019, 114, 1626-1635.	0.2	65
152	Clinical significance of hepatic steatosis according to coronary plaque morphology: assessment using controlled attenuation parameter. <i>Journal of Gastroenterology</i> , 2019, 54, 271-280.	2.3	21
153	Controlled Attenuation Parameter for Assessment of Hepatic Steatosis in Indian Patients. <i>Journal of Clinical and Experimental Hepatology</i> , 2019, 9, 13-21.	0.4	24
154	Noninvasive Measurements Predict Liver Fibrosis Well in Hepatitis C Virus Patients After Direct-Acting Antiviral Therapy. <i>Digestive Diseases and Sciences</i> , 2020, 65, 1491-1500.	1.1	32
155	The performance of M and XL probes of FibroScan for the diagnosis of steatosis and fibrosis on a Brazilian nonalcoholic fatty liver disease cohort. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 231-238.	0.8	13
156	Ulcerative Colitis as an Independent Risk Factor for Hepatic Steatosis. <i>Gastroenterology Nursing</i> , 2020, 43, 292-297.	0.2	11
157	Use of imaging techniques for non-invasive assessment in the diagnosis and staging of non-alcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2020, 112, 154355.	1.5	23
158	One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 3213.	1.0	14
159	Randomized Clinical Trial: Bergamot Citrus and Wild Cardoon Reduce Liver Steatosis and Body Weight in Non-diabetic Individuals Aged Over 50 Years. <i>Frontiers in Endocrinology</i> , 2020, 11, 494.	1.5	33
160	Hepatic steatosis and liver fat contents in liver transplant recipients are associated with serum adipokines and insulin resistance. <i>Scientific Reports</i> , 2020, 10, 12701.	1.6	8
161	Diagnostic performance of fibroscan and computed tomography in 322 normal alanine aminotransferase non-obese non-alcoholic fatty liver disease patients diagnosed by ultrasound. <i>International Journal of Clinical Practice</i> , 2020, 74, e13635.	0.8	3
162	Higher cut-off values of non-invasive methods might be needed to detect moderate-to-severe steatosis in morbid obese patients: a pilot study. <i>Scientific Reports</i> , 2020, 10, 15007.	1.6	2
163	<p>Correlation Between Psoriasis Severity and Nonalcoholic Fatty Liver Disease Degree Measured Using Controlled Attenuation Parameter</p>. <i>Psoriasis: Targets and Therapy</i> , 2020, Volume 10, 39-44.	1.2	6
164	Plasma phospholipid dysregulation in patients with cystathionine-Î² synthase deficiency. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 2286-2295.	1.1	4

#	ARTICLE	IF	CITATIONS
165	Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease. <i>Liver International</i> , 2020, 40, 3061-3070.	1.9	13
166	The Prevalence and Determinants of Hepatic Steatosis Assessed by Controlled Attenuation Parameter in Thai Chronic Hepatitis C Patients. <i>Gastroenterology Research and Practice</i> , 2020, 2020, 1-7.	0.7	3
167	&lt;p&gt;Association of Serum Fibroblast Growth Factor 23 Levels with the Presence and Severity of Hepatic Steatosis Is Independent of Sleep Duration in Patients with Diabetes&lt;/p&gt;. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020, Volume 13, 1171-1178.	1.1	3
168	Noninvasive monitoring of liver fat during treatment with GLP&#x1 analogues and SGLT&#x2 inhibitors in a real&#x world setting. <i>Endocrinology, Diabetes and Metabolism</i> , 2020, 3, e00131.	1.0	6
169	Association between Non-Alcoholic Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1635.	1.0	11
170	Transient elastography: a novel, non-invasive method for the evaluation of liver stiffness and controlled attenuation parameter in cows. <i>Journal of Veterinary Medical Science</i> , 2020, 82, 559-565.	0.3	1
171	The Role of Multiparametric US of the Liver for the Evaluation of Nonalcoholic Steatohepatitis. <i>Radiology</i> , 2020, 296, 532-540.	3.6	122
172	Vitamin D for treatment of non&#x alcoholic fatty liver disease detected by transient elastography: A randomized, double&#x blind, placebo&#x controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2097-2106.	2.2	17
173	Improvement in liver stiffness measurement for diagnosis of liver fibrosis in patients with concurrent chronic hepatitis B and nonalcoholic fatty liver disease. <i>Journal of International Medical Research</i> , 2020, 48, 030006052090366.	0.4	3
174	A Pilot Study on the Effect of Anti-Thrombopoietin Antibody on Platelet Count in Patients with Type 2 Diabetes. <i>Molecules</i> , 2020, 25, 1667.	1.7	2
175	The Utility of Assessing Liver Allograft Fibrosis and Steatosis Post&#x Liver Transplantation Using Transient Elastography With Controlled Attenuation Parameter. <i>Transplantation Proceedings</i> , 2021, 53, 159-165.	0.3	15
176	La utilidad cl&#x nica de la elastograf&#x a transitoria como una herramienta de imagenolog&#x a para evaluar el impacto a corto plazo de la gastrectom&#x a laparosc&#x pica en manga, en conjunto con par&#x metros cl&#x nicos y bioqu&#x micos e &#x ndices cl&#x nico-bioqu&#x micos en pacientes con enfermedad de h&#x gado graso no alcoh&#x lico: un estudio piloto egipcio. <i>Revista De Gastroenterolog&amp;#x a De M&amp;#x xico</i> , 2021, 86, 125-132.	0.4	0
177	Prevalence of non-alcoholic fatty liver disease and its associated factors in individuals with type 1 diabetes: a cross-sectional study in a tertiary care center in Brazil. <i>Diabetology and Metabolic Syndrome</i> , 2021, 13, 33.	1.2	9
178	Controlled Attenuation Parameter for Quantification of Steatosis: Which Cut-Offs to Use?. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-7.	0.8	22
179	Clinical utility of transient elastography as an imaging tool to assess the short-term impact of laparoscopic sleeve gastrectomy, together with clinical and biochemical parameters and clinico-biochemical indices, on obese patients with nonalcoholic fatty liver disease: An Egyptian pilot study. <i>Revista De Gastroenterolog&amp;#x a De M&amp;#x xico (English Edition)</i> , 2021, 86, 125-132.	0.1	0
180	The prevalence of metabolic associated fatty liver detected by FibroScan&#x in women with gestational diabetes in a multiethnic population. <i>Diabetes Research and Clinical Practice</i> , 2021, 174, 108757.	1.1	3
181	Metabolic Evaluation in Patients With Hepatitis C Treated With Direct Antiviral Agents. <i>Frontiers in Medicine</i> , 2021, 8, 631600.	1.2	5
182	The association of adiponectin gene polymorphisms with susceptibility and progression of NAFLD in a cohort of Egyptian patients. <i>Egyptian Liver Journal</i> , 2021, 11, .	0.3	3

#	ARTICLE	IF	CITATIONS
183	Noninvasive Assessment of Hepatitis C Virus Infected Patients Using Vibration-Controlled Transient Elastography. <i>Journal of Clinical Medicine</i> , 2021, 10, 2575.	1.0	4
184	Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection. <i>Hepatology International</i> , 2021, 15, 901-911.	1.9	24
185	Quantitative assessment of liver steatosis using ultrasound controlled attenuation parameter (Echosens). <i>Journal of Medical Ultrasonics (2001)</i> , 2021, 48, 489-495.	0.6	14
186	Conventional ultrasound for diagnosis of hepatic steatosis is better than believed. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, 1235-1248.	0.2	12
187	Reassessment of the Hispanic Disparity: Hepatic Steatosis Is More Prevalent in Mexican Americans Than Other Hispanics. <i>Hepatology Communications</i> , 2021, 5, 2068-2079.	2.0	12
188	Feasibility of Fibroscan in Assessment of Hepatic Steatosis and Fibrosis in Obese Patients: Report From a General Internal Medicine Clinic. , 2021, 32, 466-472.		5
189	Short-term Safety of Repeated Acetaminophen Use in Patients With Compensated Cirrhosis. <i>Hepatology Communications</i> , 2022, 6, 361-373.	2.0	10
190	Quantitative assessment of fatty liver using ultrasound attenuation imaging. <i>Journal of Medical Ultrasonics (2001)</i> , 2021, 48, 465-470.	0.6	9
191	Antenatal FibroScan Â® assessment for metabolic associated fatty liver in pregnant women at risk of gestational diabetes from a multiethnic population â€“ a pilot study. <i>Internal Medicine Journal</i> , 2021, , .	0.5	0
192	A dynamic association between myosteatorosis and liver stiffness: Results from a prospective interventional study in obese patients. <i>JHEP Reports</i> , 2021, 3, 100323.	2.6	24
193	The Association between Low Muscle Mass and Hepatic Steatosis in Asymptomatic Population in Korea. <i>Life</i> , 2021, 11, 848.	1.1	3
194	Multiparametric US for Identifying Patients with High-Risk NASH: A Derivation and Validation Study. <i>Radiology</i> , 2021, 301, 625-634.	3.6	20
195	Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study. <i>Cardiovascular Diabetology</i> , 2021, 20, 193.	2.7	17
196	Noninvasive Estimation of Hepatic Steatosis by Controlled Attenuation Parameter in Living Donor Liver Transplant. <i>Experimental and Clinical Transplantation</i> , 2022, 20, 674-679.	0.2	1
197	M probe comes first: Impact of initial probe choice on diagnostic performance of vibration controlled transient elastography. <i>Digestive and Liver Disease</i> , 2022, 54, 358-364.	0.4	5
198	Quantification of Liver Fat Content with Ultrasound: A WFUMB Position Paper. <i>Ultrasound in Medicine and Biology</i> , 2021, 47, 2803-2820.	0.7	63
199	Microbiota analysis and transient elastography reveal new extra-hepatic components of liver steatosis and fibrosis in obese patients. <i>Scientific Reports</i> , 2021, 11, 659.	1.6	29
200	Assessment of hepatic fibrosis and steatosis by vibration-controlled transient elastography and controlled attenuation parameter versus non-invasive assessment scores in patients with non-alcoholic fatty liver disease. <i>Egyptian Liver Journal</i> , 2020, 10, .	0.3	8

#	ARTICLE	IF	CITATIONS
201	Factors Affecting the Accuracy of Controlled Attenuation Parameter (CAP) in Assessing Hepatic Steatosis in Patients with Chronic Liver Disease. PLoS ONE, 2014, 9, e98689.	1.1	33
202	Stereological Analysis of Liver Biopsy Histology Sections as a Reference Standard for Validating Non-Invasive Liver Fat Fraction Measurements by MRI. PLoS ONE, 2016, 11, e0160789.	1.1	20
203	Significant liver fibrosis assessed using liver transient elastography is independently associated with low bone mineral density in patients with non-alcoholic fatty liver disease. PLoS ONE, 2017, 12, e0182202.	1.1	26
204	A prospective comparative assessment of the accuracy of the FibroScan in evaluating liver steatosis. PLoS ONE, 2017, 12, e0182784.	1.1	36
205	The relationship between visceral obesity and hepatic steatosis measured by controlled attenuation parameter. PLoS ONE, 2017, 12, e0187066.	1.1	24
206	Noninvasive Quantitative Detection Methods of Liver Fat Content in Nonalcoholic Fatty Liver Disease. Journal of Clinical and Translational Hepatology, 2018, 6, 217-221.	0.7	38
207	Short-term Dietary Interventions for the Management of Nonalcoholic Fatty Liver. Current Medicinal Chemistry, 2019, 26, 3483-3496.	1.2	3
208	Non-Invasive Assessment of Non-Alcoholic Fatty Liver Disease: Ultrasound and Transient Elastography. Reviews on Recent Clinical Trials, 2015, 9, 170-177.	0.4	12
209	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clinical and Molecular Hepatology, 2013, 19, 325.	4.5	105
210	Application of transient elastography in nonalcoholic fatty liver disease. Clinical and Molecular Hepatology, 2020, 26, 128-141.	4.5	70
211	Non-alcoholic fatty liver disease and transient elastography. Exploration of Medicine, 2020, 1, 205-217.	1.5	4
212	Controlled attenuation parameter for evaluating liver steatosis in chronic viral hepatitis. World Journal of Gastroenterology, 2014, 20, 6626.	1.4	37
213	Diagnostic value of controlled attenuation parameter for liver steatosis in patients with chronic hepatitis B. World Journal of Gastroenterology, 2014, 20, 10585.	1.4	17
214	Noninvasive imaging assessment of non-alcoholic fatty liver disease: Focus on liver scintigraphy. World Journal of Gastroenterology, 2015, 21, 4432-4439.	1.4	7
215	Ultrasound-based techniques for the diagnosis of liver steatosis. World Journal of Gastroenterology, 2019, 25, 6053-6062.	1.4	240
216	Severity of Nonalcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus: Relationship between Nongenetic Factors and PNPLA3/HSD17B13 Polymorphisms. Diabetes and Metabolism Journal, 2019, 43, 700.	1.8	20
217	Impaired Fat Oxidation and Reduced Resting Energy Expenditure after a Fat Load in Individuals with Liver Steatosis. Journal of Nutrition & Food Sciences, 2018, 08, .	1.0	1
218	Transient elastography: Kill two birds with one stone?. World Journal of Hepatology, 2013, 5, 264.	0.8	77

#	ARTICLE	IF	CITATIONS
219	Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease. World Journal of Hepatology, 2015, 7, 638.	0.8	68
220	Usefulness of the Controlled Attenuation Parameter for Detecting Liver Steatosis in Health Checkup Examinees. Gut and Liver, 2015, 9, 405-10.	1.4	10
221	Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease. Gut and Liver, 2016, 10, 295.	1.4	14
222	Transient Elastography in Methotrexate Administered Patients. Hepatitis Monthly, 2017, 17, .	0.1	2
224	The Diagnosis of Nonalcoholic Fatty Liver Disease. Korean Journal of Medicine, 2014, 86, 405.	0.1	1
225	Liver stiffness measurement by transient elastography (FibroScan). Choonpa Igaku, 2015, 42, 477-485.	0.0	1
227	Improvement of Diagnostic Algorithm in Patients With Alcoholic Fatty Liver Disease by Using Non-invasive Methods of Verification of Liver Steatosis and Fibrosis. Lviv Clinical Bulletin, 2016, 1, 58-64.	0.1	0
228	Transient Elasto graphy- The Newer Technique for Noninvasive Assessment of Liver Fibrosis. Advanced Research in Gastroenterology & Hepatology, 2017, 4, .	0.1	0
229	Elastography in the Diagnosis of Non-Alcoholic Fatty Liver Disease. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2019, 74, 5-13.	0.2	3
230	Prevalence of fatty liver disease in patients with inflammatory bowel disease: a transient elastography study on the basis of a controlled attenuation parameter. Marmara Medical Journal, 2019, 32, 68-70.	0.2	4
231	Relationships between ultrasonic, immunological changes in the progression of liver steatosis and fibrosis in patients with chronic diffusive liver diseases of various etiologies. PatologĀa, 2019, .	0.1	0
232	EVALUATION OF PROGRESSION OF HEPATIC FIBROSIS IN A GROUP OF PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE ACCOMPANIED FOR 10 YEARS. Arquivos De Gastroenterologia, 2019, 56, 256-260.	0.3	6
233	Bacterial overgrowth syndrome in patients with chronic diffuse liver diseases depending on the etiology and morphological features. Gastroenterologia, 2019, 53, 162-169.	0.0	0
234	Noninvasive methods of diagnosis of steatosis in non-alcoholic fatty liver disease. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2020, 174, 61-66.	0.1	2
235	Lifestyle and silymarin: a fight against liver damage in NAFLD associated - prediabetic disease. Journal of Diabetes and Metabolic Disorders, 2020, 19, 883-894.	0.8	4
236	The defining of the reference range of liver stiffness and fat attenuation parameter for healthy Chinese children. European Journal of Gastroenterology and Hepatology, 2021, 33, 1394-1399.	0.8	2
237	Non-invasive diagnosis of non-alcoholic fatty liver disease in children: role of shear-wave elastography and steatometry. ZdorovĒe Rebenka, 2020, 15, 409-419.	0.0	0
239	Diagnosis of hepatic steatosis in non-alcoholic fatty liver disease in the military. Vestnik of Russian Military Medical Academy, 2020, 22, 100-104.	0.1	0

#	ARTICLE	IF	CITATIONS
240	Diagnostic accuracy of apoptosis markers in non-alcoholic fatty liver disease in children. <i>PatologÃ</i> , 2020, .	0.1	0
241	Steatosis Assessment with Controlled Attenuation Parameter (CAP) in Various Diseases. , 2020, , 441-457.		0
242	Steatosis Assessment by Controlled Attenuation Parameter (CAPâ„†). , 2020, , 413-439.		0
243	Non-invasive Assessment of Non-alcoholic Fatty Liver Disease: Ultrasound and Transient Elastography. , 2020, , 115-139.		1
244	Regular coffee intake improves liver enzyme levels and liver histology in patients with chronic alcohol consumption, non-alcoholic fatty liver and non-alcoholic steatohepatitis: Report of 259 cases. <i>Hepatology Forum</i> , 2020, , .	0.3	0
245	Imaging methods in the assessment of nonalcoholic fatty liver disease. <i>Radiologia Brasileira</i> , 2020, 53, IX-X.	0.3	1
246	Correlation of the grade of hepatic steatosis between controlled attenuation parameter and ultrasound in patients with fatty liver: a multi-center retrospective cohort study. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 1346-1353.	0.7	3
247	Diagnostic Assessment of Nonalcoholic Fatty Liver Disease. <i>Korean Journal of Medicine</i> , 2020, 95, 299-307.	0.1	0
249	Sonographic assessment of fatty liver: intraobserver and interobserver variability. <i>International Journal of Clinical and Experimental Medicine</i> , 2014, 7, 5453-60.	1.3	31
250	Controlled attenuation parameter for assessment of hepatic steatosis grades: a diagnostic meta-analysis. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 17654-63.	1.3	40
251	Comparing different non-invasive methods in assessment of the effects of curcumin on hepatic fibrosis in patients with non-alcoholic fatty liver disease. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2018, 11, S8-S13.	0.6	7
252	Screening for undiagnosed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): A population-based risk factor assessment using vibration controlled transient elastography (VCTE). <i>PLoS ONE</i> , 2021, 16, e0260320.	1.1	10
253	Ultrasonographic index for the diagnosis of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease. <i>Quantitative Imaging in Medicine and Surgery</i> , 2022, 12, 1815-1829.	1.1	3
254	Association between liver stiffness measurement by transient elastography and chronic kidney disease. <i>Medicine (United States)</i> , 2022, 101, e28658.	0.4	2
255	Validation and Performance of FibroScan®-AST (FAST) Score on a Brazilian Population with Nonalcoholic Fatty Liver Disease. <i>Digestive Diseases and Sciences</i> , 2022, 67, 5272-5279.	1.1	4
256	Quantitative Evaluation of Hepatic Steatosis Using Advanced Imaging Techniques: Focusing on New Quantitative Ultrasound Techniques. <i>Korean Journal of Radiology</i> , 2022, 23, 13.	1.5	18
257	Magnetic Resonance Imaging-Proton Density Fat Fraction vs. Transient Elastography-Controlled Attenuation Parameter in Diagnosing Non-alcoholic Fatty Liver Disease in Children and Adolescents: A Meta-Analysis of Diagnostic Accuracy. <i>Frontiers in Pediatrics</i> , 2021, 9, 784221.	0.9	14
258	Association between bedtime at night and nonalcoholic fatty liver disease diagnosed by liver ultrasound transient elastography. <i>Diabetes Research and Clinical Practice</i> , 2022, 184, 109195.	1.1	6

#	ARTICLE	IF	CITATIONS
259	Rural-Urban differentials in prevalence, spectrum and determinants of Non-alcoholic Fatty Liver Disease in North Indian population. PLoS ONE, 2022, 17, e0263768.	1.1	7
260	La stéato-hépatite non alcoolique - Une affection métabolique aux multiples facettes et un challenge hépatologique. HEGEL - Hépatogastroentérologie Libérale, 2014, N° 1, 2-11.	0.0	0
261	Positive Pattern Recognition System Using Alanine Aminotransferase, Type IV Collagen 7s, and E Value (Liver Stiffness) for the Diagnosis of Nonalcoholic Steatohepatitis Based on Natural History. JMA Journal, 2022, 5, .	0.6	1
262	Liver Ultrasound Attenuation. Ultrasound Quarterly, 2022, Publish Ahead of Print, .	0.3	4
263	The association between Helicobacter pylori with nonalcoholic fatty liver disease assessed by controlled attenuation parameter and other metabolic factors. PLoS ONE, 2021, 16, e0260994.	1.1	7
266	General Overview About the Current Management of Nonalcoholic Fatty Liver Disease. Clinical Drug Investigation, 2022, 42, 39-45.	1.1	4
267	Frequency of Acute and Chronic Liver Diseases Diagnosed on Computed Tomography. Pakistan Biomedical Journal, 0, , .	0.0	0
268	Systematic screening for advanced liver fibrosis in patients with coronary artery disease: The CORONASH study. PLoS ONE, 2022, 17, e0266965.	1.1	4
269	Population-specific cut-off points of fatty liver index: a study based on the National Health and Nutrition Examination Survey data. BMC Gastroenterology, 2022, 22, .	0.8	3
270	Prevalence and Risk Factors for Hepatic Steatosis in Children With Perinatal HIV on Early Antiretroviral Therapy Compared to HIV-Exposed Uninfected and HIV-Unexposed Children. Frontiers in Pediatrics, 0, 10, .	0.9	5
271	Carotid intima media as predictor of liver fibrosis in type 2 diabetes mellitus with NAFLD. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102560.	1.8	3
272	Correlation between hepatorenal index and attenuation imaging for assessing hepatic steatosis. Australasian Journal of Ultrasound in Medicine, 0, , .	0.3	2
273	European guideline on obesity care in patients with gastrointestinal and liver diseases “ Joint ESPEN/UEG guideline. Clinical Nutrition, 2022, , .	2.3	22
274	Controlled attenuation parameter accurately detects liver steatosis in people with HIV. Aids, 2022, 36, 2147-2152.	1.0	4
275	Modifications decrease hepatic steatosis in Taiwanese with metabolic-associated fatty liver disease. Kaohsiung Journal of Medical Sciences, 0, , .	0.8	1
276	Ultrasound and FibroScan® Controlled Attenuation Parameter in patients with MAFLD: head to head comparison in assessing liver steatosis. Endocrine, 0, , .	1.1	2
277	European guideline on obesity care in patients with gastrointestinal and liver diseases “ Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline. United European Gastroenterology Journal, 2022, 10, 663-720.	1.6	18
278	Long non-coding RNA in Non-alcoholic fatty liver disease. Advances in Clinical Chemistry, 2022, , 1-35.	1.8	4



#	ARTICLE	IF	CITATIONS
279	Speed of sound index for liver steatosis estimation: a reliability study in normal subjects. , 2022, 28, 418-427.		0
280	Indian patients with human immunodeficiency virus infection have high prevalence but mild severity of non-alcoholic fatty liver disease. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102679.	1.8	3
281	Impact of hepatic steatosis on treatment response of autoimmune hepatitis: A retrospective multicentre analysis. Frontiers in Immunology, 0, 13, .	2.2	0
282	Screening for NAFLD and its severity in type 2 diabetic patients: value of magnetic resonance imaging and outstanding issues. Journal of Hepatology, 2022, , .	1.8	1
283	Controlled attenuation parameter-insulin resistance (CIR) score to predict non-alcoholic steatohepatitis. Scientific Reports, 2022, 12, .	1.6	1
284	Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD). Journal of Clinical and Experimental Hepatology, 2023, 13, 273-302.	0.4	16
285	Diagnostic accuracy of inflammation and insulin resistance markers in non-alcoholic fatty liver disease in children. ZdorovĚie Rebenka, 2022, 17, 326-333.	0.0	0
286	Adipose Tissue, Metabolic Syndrome, and Non-Alcoholic Fatty Liver Disease â€“ A Short Review. European Medical Journal Hepatology, 0, , 62-70.	1.0	2
287	Performance of twoâ€dimensional shear wave elastography and transient elastography compared to liver biopsy for staging of liver fibrosis. European Journal of Clinical Investigation, 2023, 53, .	1.7	3
288	Decreased Hepatic Steatosis in South African Adolescents With Perinatal HIV Switching to Dolutegravir-containing Regimens. Pediatric Infectious Disease Journal, 2023, 42, 564-572.	1.1	0
289	Serum Cardiotrophin-1 Concentration Is Negatively Associated with Controlled Attenuation Parameters in Subjects with Non-Alcoholic Fatty Liver Disease. Journal of Clinical Medicine, 2023, 12, 2741.	1.0	0
298	Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter for Staging Nonalcoholic Fatty Liver Disease. , 2023, , 107-122.		0